Heart failure and chronic obstructive pulmonary disease: The challenges facing physicians and health services

European Heart Journal

Volumn 34, Issue 36, 2013, Pages

  Hawkins, Nathaniel M ^a   Virani, Sean ^b   Ceconi, Claudio ^c  

^a LIVERPOOL HEART AND CHEST HOSPITAL   (United Kingdom)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^c UNIVERSITY HOSPITAL OF FERRARA   (Italy)

Author keywords

Adrenergic beta agonists; Adrenergic beta antagonists; Chronic obstructive pulmonary disease; Heart failure

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; BISOPROLOL; BRONCHODILATING AGENT; CARVEDILOL; CORTICOSTEROID; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FLUTICASONE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; METOPROLOL; NATRIURETIC FACTOR; PLACEBO; VILANTEROL;

AIRWAY OBSTRUCTION; CARDIOVASCULAR MAGNETIC RESONANCE; CARDIOVASCULAR RISK; CHRONIC OBSTRUCTIVE LUNG DISEASE; COMPARATIVE STUDY; CONTRAST ECHOCARDIOGRAPHY; DISEASE CLASSIFICATION; DISEASE EXACERBATION; DISEASE SEVERITY; ECHOCARDIOGRAPHY; FORCED EXPIRATORY VOLUME; HEALTH CARE COST; HEALTH CARE SYSTEM; HEALTH CARE UTILIZATION; HEALTH SERVICE; HEART ARRHYTHMIA; HEART FAILURE; HOSPITALIZATION; HUMAN; HYPOKALEMIA; INFLAMMATION; ISCHEMIA; LUNG EDEMA; LUNG FUNCTION TEST; OBSERVATIONAL STUDY; PATHOPHYSIOLOGY; PHYSICIAN; PREVALENCE; PRIORITY JOURNAL; PROGNOSIS; PULMONARY HYPERTENSION; QT PROLONGATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; TACHYCARDIA; TREATMENT OUTCOME;

ADRENERGIC BETA-AGONISTS; ADRENERGIC BETA-ANTAGONISTS; CHRONIC OBSTRUCTIVE PULMONARY DISEASE; HEART FAILURE;

ADRENERGIC BETA-AGONISTS; ADRENERGIC BETA-ANTAGONISTS; COSTS AND COST ANALYSIS; DIAGNOSIS, DIFFERENTIAL; DRUG THERAPY, COMBINATION; EARLY DIAGNOSIS; ECHOCARDIOGRAPHY; GENETIC PREDISPOSITION TO DISEASE; HEART FAILURE; HUMANS; NATRIURETIC PEPTIDES; PRACTICE GUIDELINES AS TOPIC; PROGNOSIS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RESPIRATORY FUNCTION TESTS; RISK FACTORS;

EID: 84884895703     PISSN: 0195668X     EISSN: 15229645     Source Type: Journal    
DOI: 10.1093/eurheartj/eht192     Document Type: Review

References (158)

1. Lozano R, Naghavi M, Foreman K, Lim S, Shibuya K, Aboyans V, Abraham J, Adair T, Aggarwal R, Ahn SY, Alvarado M, Anderson HR, Anderson LM, Andrews KG, Atkinson C, Baddour LM, Barker-Collo S, Bartels DH, Bell ML, Benjamin EJ, Bennett D, Bhalla K, Bikbov B, Bin Abdulhak A, Birbeck G, Blyth F, Bolliger I, Boufous S, Bucello C, Burch M, Burney P, Carapetis J, Chen H, Chou D, Chugh SS, Coffeng LE, Colan SD, Colquhoun S, Colson KE, Condon J, Connor MD, Cooper LT, Corriere M, Cortinovis M, de Vaccaro KC, Couser W, Cowie BC, Criqui MH, Cross M, Dabhadkar KC, Dahodwala N, De Leo D, Degenhardt L, Delossantos A, Denenberg J, Des Jarlais DC, Dharmaratne SD, Dorsey ER, Driscoll T, Duber H, Ebel B, Erwin PJ, Espindola P, Ezzati M, Feigin V, Flaxman AD, Forouzanfar MH, Fowkes FG, Franklin R, Fransen M, Freeman MK, Gabriel SE, Gakidou E, Gaspari F, Gillum RF, Gonzalez-Medina D, Halasa YA, Haring D, Harrison JE, Havmoeller R, Hay RJ, Hoen B, Hotez PJ, Hoy D, Jacobsen KH, James SL, Jasrasaria R, Jayaraman S, Johns N, Karthikeyan G, Kassebaum N, Keren A, Khoo JP, Knowlton LM, Kobusingye O, Koranteng A, Krishnamurthi R, Lipnick M, Lipshultz SE, Ohno SL, Mabweijano J, MacIntyre MF, Mallinger L, March L, Marks GB, Marks R, Matsumori A, Matzopoulos R, Mayosi BM, McAnulty JH, McDermott MM, McGrath J, Mensah GA, Merriman TR, Michaud C, Miller M, Miller TR, Mock C, Mocumbi AO, Mokdad AA, Moran A, Mulholland K, Nair MN, Naldi L, Narayan KM, Nasseri K, Norman P, O'Donnell M, Omer SB, Ortblad K, Osborne R, Ozgediz D, Pahari B, Pandian JD, Rivero AP, Padilla RP, Perez-Ruiz F, Perico N, Phillips D, Pierce K, Pope CA 3rd, Porrini E, Pourmalek F, Raju M, Ranganathan D, Rehm JT, Rein DB, Remuzzi G, Rivara FP, Roberts T, De Leon FR, Rosenfeld LC, Rushton L, Sacco RL, Salomon JA, Sampson U, Sanman E, Schwebel DC, Segui-Gomez M, Shepard DS, Singh D, Singleton J, Sliwa K, Smith E, Steer A, Taylor JA, Thomas B, Tleyjeh IM, Towbin JA, Truelsen T, Undurraga EA, Venketasubramanian N, Vijayakumar L, Vos T, Wagner GR, Wang M, Wang W, Watt K, Weinstock MA, Weintraub R, Wilkinson JD, Woolf AD, Wulf S, Yeh PH, Yip P, Zabetian A, Zheng ZJ, Lopez AD, Murray CJ, AlMazroa MA, Memish ZA. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the global burden of disease study 2010. Lancet 2012; 380: 2095-2128.
2. Hawkins NM, Petrie MC, Jhund PS, Chalmers GW, Dunn FG, McMurray JJ. Heart failure and chronic obstructive pulmonary disease: diagnostic pitfalls and epidemiology. Eur J Heart Fail 2009; 11: 130-139.
3. Hawkins NM, Petrie MC, Macdonald MR, Jhund PS, Fabbri LM, Wikstrand J, McMurray JJ. Heart failure and chronic obstructive pulmonary disease the quandary of beta-blockers and beta-agonists. J Am Coll Cardiol 2011; 57: 2127-2138.
4. HawkinsNM, Jhund PS, McMurray JJ, Capewell S. Heart failure and socioeconomic status: accumulating evidence of inequality. Eur J Heart Fail 2012; 14: 138-146.
5. Gershon AS, Dolmage TE, Stephenson A, Jackson B. Chronic obstructive pulmonary disease and socioeconomic status: a systematic review. COPD 2012; 9: 216-226.
6. Hawkins NM, Wright DJ, Capewell S. Heart failure services in the United Kingdom: rethinking the machine bureaucracy. Int J Cardiol 2013; 162: 143-148.
7. Barnett K, Mercer SW, Norbury M, Watt G, Wyke S, Guthrie B. Epidemiology of multimorbidity and implications for health care, research, and medical education: a cross-sectional study. Lancet 2012; 380: 37-43.
8. McMurray JJ, Adamopoulos S, Anker SD, Auricchio A, Bohm M, Dickstein K, Falk V, Filippatos G, Fonseca C, Gomez-Sanchez MA, Jaarsma T, Kober L, Lip GY, Maggioni AP, Parkhomenko A, Pieske BM, Popescu BA, Ronnevik PK, Rutten FH, Schwitter J, Seferovic P, Stepinska J, Trindade PT, Voors AA, Zannad F, Zeiher A, Guidelines ESCCfP, Bax JJ, Baumgartner H, Ceconi C, Dean V, Deaton C, Fagard R, Funck-Brentano C, Hasdai D, Hoes A, Kirchhof P, Knuuti J, Kolh P, McDonagh T, Moulin C, Reiner Z, Sechtem U, Sirnes PA, Tendera M, Torbicki A, Vahanian A, Windecker S, Document R, Bonet LA, Avraamides P, Ben Lamin HA, Brignole M, Coca A, Cowburn P, Dargie H, Elliott P, Flachskampf FA, Guida GF, Hardman S, Iung B, Merkely B, Mueller C, Nanas JN, Nielsen OW, Orn S, Parissis JT, Ponikowski P. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the heart failure association (HFA) of the ESC. Eur Heart J 2012; 33: 1787-1847.
9. Vestbo J, Hurd SS, Agusti AG, Jones PW, Vogelmeier C, Anzueto A, Barnes PJ, Fabbri LM, Martinez FJ, Nishimura M, Stockley RA, Sin DD, Rodriguez-Roisin R. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med 2013; 187: 347-365.
10. Qaseem A, Wilt TJ, Weinberger SE, Hanania NA, Criner G, van der Molen T, Marciniuk DD, Denberg T, Schunemann H, Wedzicha W, MacDonald R, Shekelle P, American College of Physicians, American College of Chest Physicians, American Thoracic Society, European Respiratory Society. Diagnosis and management of stable chronic obstructive pulmonary disease: a clinical practice guideline update from the American College of Physicians, American College of Chest Physicians, American Thoracic Society, and European Respiratory Society. Ann Intern Med 2011; 155: 179-191.
11. Celli BR, Halbert RJ. Point: should we abandon fev(1)/fvc, 0.70 to detect airway obstruction? No. Chest 2010; 138: 1037-1040.
12. Pellegrino R, Viegi G, Brusasco V, Crapo RO, Burgos F, Casaburi R, Coates A, van der Grinten CP, Gustafsson P, Hankinson J, Jensen R, Johnson DC, MacIntyre N, McKay R, Miller MR, Navajas D, Pedersen OF, Wanger J. Interpretative strategies for lung function tests. Eur Respir J 2005; 26: 948-968.
13. Swanney MP, Ruppel G, Enright PL, Pedersen OF, Crapo RO, Miller MR, Jensen RL, Falaschetti E, Schouten JP, Hankinson JL, Stocks J, Quanjer PH. Using the lower limit of normal for the fev1/fvc ratio reduces the misclassification of airway obstruction. Thorax 2008; 63: 1046-1051.
14. Dzau VJ, Antman EM, Black HR, Hayes DL, Manson JE, Plutzky J, Popma JJ, Stevenson W. The cardiovascular disease continuum validated: clinical evidence of improved patient outcomes: Part i: pathophysiology and clinical trial evidence (risk factors through stable coronary artery disease). Circulation 2006; 114: 2850-2870.
15. Ukena C, Mahfoud F, Kindermann M, Kindermann I, Bals R, Voors AA, van Veldhuisen DJ, Bohm M. The cardiopulmonary continuum systemic inflammation as 'common soil' of heart and lung disease. Int J Cardiol 2010; 145: 172-176.
16. Sin DD, Man SF. Chronic obstructive pulmonary disease as a risk factor for cardiovascular morbidity and mortality. Proc Am Thorac Soc 2005; 2: 8-11.
17. Libby P, Ridker PM, Maseri A. Inflammation and atherosclerosis. Circulation 2002; 105: 1135-1143.
18. Sin DD, Man SF. Why are patients with chronic obstructive pulmonary disease at increased risk of cardiovascular diseases? The potential role of systemic inflammation in chronic obstructive pulmonary disease. Circulation 2003; 107: 1514-1519.
19. Watz H, Waschki B, Kirsten A, Muller KC, Kretschmar G, Meyer T, Holz O, Magnussen H. The metabolic syndrome in patients with chronic bronchitis and COPD: frequency and associated consequences for systemic inflammation and physical inactivity. Chest 2009; 136: 1039-1046.
20. Poulain M, Doucet M, Major GC, Drapeau V, Series F, Boulet LP, Tremblay A, Maltais F. The effect of obesity on chronic respiratory diseases: pathophysiology and therapeutic strategies. CMAJ 2006; 174: 1293-1299.
21. Fabbri LM, Rabe KF. From COPD to chronic systemic inflammatory syndrome? Lancet 2007; 370: 797-799.
22. Yanbaeva DG, Dentener MA, Creutzberg EC, Wesseling G, Wouters EF. Systemic effects of smoking. Chest 2007; 131: 1557-1566.
23. Agusti A. Chronic obstructive pulmonary disease: a systemic disease. Proc Am Thorac Soc 2006; 3: 478-481.
24. Viegi G, Maio S, Pistelli F, Baldacci S, Carrozzi L. Epidemiology of chronic obstructive pulmonary disease: health effects of air pollution. Respirology 2006; 11: 523-532.
25. Hoffmann B, Moebus S, Dragano N, Stang A, Mohlenkamp S, Schmermund A, Memmesheimer M, Brocker-Preuss M, Mann K, Erbel R, Jockel KH. Chronic residential exposure to particulate matter air pollution and systemic inflammatory markers. Environ Health Perspect 2009; 117: 1302-1308.
26. Fabbri LM, Luppi F, Beghe B, Rabe KF. Complex chronic comorbidities of COPD. Eur Respir J 2008; 31: 204-212.
27. Boschetto P, Beghe B, Fabbri LM, Ceconi C. Link between chronic obstructive pulmonary disease and coronary artery disease: implication for clinical practice. Respirology 2012; 17: 422-431.
28. Sevenoaks MJ, Stockley RA. Chronic obstructive pulmonary disease, inflammation and co-morbidity-a common inflammatory phenotype? Respir Res 2006; 7: 70.
29. Ceconi C, Boraso A, Mele D, Guardigli R, Ferrari R. Tnfalpha in patients with congestive heart failure. Basic Res Cardiol 2004; 99: 12-17.
30. Todd JL, Goldstein DB, Ge D, Christie J, Palmer SM. The state of genome-wide association studies in pulmonary disease: a new perspective. Am J Respir Crit Care Med 2011; 184: 873-880.
31. Zeller T, Blankenberg S, Diemert P. Genomewide association studies in cardiovascular disease-an update 2011. Clin Chem 2012; 58: 92-103.
32. Sandhu MS, Waterworth DM, Debenham SL, Wheeler E, Papadakis K, Zhao JH, Song K, Yuan X, Johnson T, Ashford S, Inouye M, Luben R, Sims M, Hadley D, McArdleW, Barter P, Kesaniemi YA, MahleyRW, McPherson R, Grundy SM, Wellcome Trust Case Control C, Bingham SA, Khaw KT, Loos RJ, Waeber G, Barroso I, Strachan DP, Deloukas P, Vollenweider P, Wareham NJ, Mooser V. LDL-cholesterol concentrations: a genome-wide association study. Lancet 2008; 371: 483-491.
33. Pillai SG, Ge D, Zhu G, Kong X, Shianna KV, Need AC, Feng S, Hersh CP, Bakke P, Gulsvik A, Ruppert A, Lodrup Carlsen KC, Roses A, Anderson W, Rennard SI, Lomas DA, Silverman EK, Goldstein DB, Investigators I.Agenome-wide association study in chronic obstructive pulmonary disease (copd): Identification of two major susceptibility loci. PLoS Genet 2009; 5: e1000421.
34. Cho MH, Boutaoui N, Klanderman BJ, Sylvia JS, Ziniti JP, Hersh CP, DeMeo DL, Hunninghake GM, Litonjua AA, Sparrow D, Lange C, Won S, Murphy JR, Beaty TH, Regan EA, Make BJ, Hokanson JE, Crapo JD, Kong X, Anderson WH, Tal-Singer R, Lomas DA, Bakke P, Gulsvik A, Pillai SG, Silverman EK. Variants in fam13a are associated with chronic obstructive pulmonary disease. Nat Genet 2010; 42: 200-202.
35. Mancini GB, Etminan M, Zhang B, Levesque LE, FitzGerald JM, Brophy JM. Reduction of morbidity and mortality by statins, angiotensin-converting enzyme inhibitors, and angiotensin receptor blockers in patients with chronic obstructive pulmonary disease. J Am Coll Cardiol 2006; 47: 2554-2560.
36. Mannino DM, Buist AS. Global burden of COPD: risk factors, prevalence, and future trends. Lancet 2007; 370: 765-773.
37. Buist AS, McBurnie MA, Vollmer WM, Gillespie S, Burney P, Mannino DM, Menezes AM, Sullivan SD, Lee TA, Weiss KB, Jensen RL, Marks GB, Gulsvik A, Nizankowska-Mogilnicka E. International variation in the prevalence of COPD (the bold study): a population-based prevalence study. Lancet 2007; 370: 741-750.
38. Menezes AM, Perez-Padilla R, Jardim JR, Muino A, LopezMV, Valdivia G, Montes de Oca M, Talamo C, Hallal PC, Victora CG. Chronic obstructive pulmonary disease in five Latin American cities (the Platino study): a prevalence study. Lancet 2005; 366: 1875-1881.
39. Halbert RJ, Natoli JL, GanoA, Badamgarav E, Buist AS, Mannino DM. Global burden of COPD: systematic review and meta-analysis. Eur Respir J 2006; 28: 523-532.
40. Lange P, Marott JL, Vestbo J, Olsen KR, Ingebrigtsen TS, Dahl M, Nordestgaard BG. Prediction of the clinical course of chronic obstructive pulmonary disease, using the new gold classification: A study of the general population. Am J Respir Crit Care Med 2012; 186: 975-981.
41. Lykkegaard J, Sondergaard J, Kragstrup J, Romhild Davidsen J, Knudsen T, Andersen M. All Danish first-time COPD hospitalisations 2002-2008: incidence, outcome, patients, and care. Respir Med 2012; 106: 549-556.
42. Groenewegen KH, Schols AM, Wouters EF. Mortality and mortality-related factors after hospitalization for acute exacerbation of copd. Chest 2003; 124: 459-467.
43. Lopez AD, Shibuya K, Rao C, Mathers CD, Hansell AL, Held LS, Schmid V, Buist S. Chronic obstructive pulmonary disease: current burden and future projections. Eur Respir J 2006; 27: 397-412.
44. Murray CJ, Lopez AD. Alternative projections of mortality and disability by cause 1990-2020: global burden of disease study. Lancet 1997; 349: 1498-1504.
45. Hawkins NM, Scholes S, Bajekal M, Love H, O'Flaherty M, Raine R, Capewell S. Community care in England: reducing socioeconomic inequalities in heart failure. Circulation 2012; 126: 1050-1057.
46. Ezekowitz JA, Kaul P, Bakal JA, Quan H, McAlister FA. Trends in heart failure care: has the incident diagnosis of heart failure shifted from the hospital to the emergency department and outpatient clinics? Eur J Heart Fail 2011; 13: 142-147.
47. Lowrie R, Mair FS, Greenlaw N, Forsyth P, Jhund PS, McConnachie A, Rae B, McMurray JJ. Pharmacist intervention in primary care to improve outcomes in patients with left ventricular systolic dysfunction. Eur Heart J 2012; 33: 314-324.
48. NielsenOW, McDonagh T, Cowburn P, Blue L, Robb SD, Dargie H. Patient differences related to management in general practice and the hospital: a cross-sectional study of heart failure in the community. Eur Heart J 2004; 25: 1718-1725.
49. Jhund PS, MacIntyre K, Simpson CR, Lewsey JD, Stewart S, Redpath A, Chalmers JW, Capewell S, McMurray JJ. Long-term trends in first hospitalization for heart failure and subsequent survival between 1986 and 2003: a population study of 5.1 million people. Circulation 2009; 119: 515-523.
50. Lenzen MJ, Scholte op Reimer WJ, Boersma E, Vantrimpont PJ, Follath F, Swedberg K, Cleland J, Komajda M. Differences between patients with a preserved and a depressed left ventricular function: a report from the Euroheart failure survey. Eur Heart J 2004; 25: 1214-1220.
51. Chapman KR, ManninoDM, Soriano JB, Vermeire PA, Buist AS, Thun MJ, Connell C, Jemal A, Lee TA, Miravitlles M, Aldington S, Beasley R. Epidemiology and costs of chronic obstructive pulmonary disease. Eur Respir J 2006; 27: 188-207.
52. Mascarenhas J, Lourenco P, Lopes R, Azevedo A, Bettencourt P. Chronic obstructive pulmonary disease in heart failure. Prevalence, therapeutic and prognostic implications. Am Heart J 2008; 155: 521-525.
53. Iversen KK, Kjaergaard J, Akkan D, Kober L, Torp-Pedersen C, Hassager C, Vestbo J, Kjoller E. Chronic obstructive pulmonary disease in patients admitted with heart failure. J Intern Med 2008; 264: 361-369.
54. Apostolovic S, Jankovic-Tomasevic R, Salinger-Martinovic S, Djordjevic- Radojkovic D, Stanojevic D, Pavlovic M, Stankovic I, Putnikovic B, Kafedzic S, Catovic S, Tahirovic E, Dungen HD. Frequency and significance of unrecognized chronic obstructive pulmonary disease in elderly patients with stable heart failure. Aging Clin Exp Res 2011; 23: 337-342.
55. Boschetto P, Fucili A, Stendardo M, Malagu M, Parrinello G, Casimirri E, Potena A, Ballerin L, Fabbri LM, Ferrari R, Ceconi C. Occurrence and impact of chronic obstructive pulmonary disease in elderly patients with stable heart failure. Respirology 2013; 18: 125-130.
56. McCullough PA, Hollander JE, Nowak RM, Storrow AB, Duc P, Omland T, McCord J, Herrmann HC, Steg PG, Westheim A, Knudsen CW, Abraham WT, Lamba S, Wu AH, Perez A, Clopton P, Krishnaswamy P, Kazanegra R, Maisel AS. Uncovering heart failure in patients with a history of pulmonary disease: rationale for the early use of B-type natriuretic peptide in the emergency department. Acad Emerg Med 2003; 10: 198-204.
57. Rutten FH, Cramer MJ, Grobbee DE, Sachs AP, Kirkels JH, Lammers JW, HoesAW. Unrecognized heart failure in elderly patients with stable chronic obstructive pulmonary disease. Eur Heart J 2005; 26: 1887-1894.
58. Macchia A, Rodriguez Moncalvo JJ, Kleinert M, Comignani PD, Gimeno G, Arakaki D, Laffaye N, Fuselli JJ, Massolin HP, Gambarte J, Romero M, Tognoni G. Unrecognised ventricular dysfunction in COPD. Eur Respir J 2012; 39: 51-58.
59. Rusinaru D, Saaidi I, Godard S, Mahjoub H, Battle C, Tribouilloy C. Impact of chronic obstructive pulmonary disease on long-term outcome of patients hospitalized for heart failure. Am J Cardiol 2008; 101: 353-358.
60. Lainscak M, Hodoscek LM, Dungen HD, Rauchhaus M, DoehnerW, Anker SD, von Haehling S. The burden of chronic obstructive pulmonary disease in patients hospitalized with heart failure. Wien Klin Wochenschr 2009; 121: 309-313.
61. Mentz RJ, Schmidt PH, Kwasny MJ, Ambrosy AP, O'Connor CM, Konstam MA, Zannad F, Maggioni AP, Swedberg K, Gheorghiade M. The impact of chronic obstructive pulmonary disease in patients hospitalized for worsening heart failure with reduced ejection fraction: an analysis of the Everest trial. J Card Fail 2012; 18: 515-523.
62. Arnaudis B, Lairez O, Escamilla R, Fouilloux A, Fournier P, Monteil B, Bouisset F, Arnal JF, Elbaz M, Carrie D, Roncalli J, Pathak A, Galinier M. Impact of chronic obstructive pulmonary disease severity on symptoms and prognosis in patients with systolic heart failure. Clin Res Cardiol 2012; 101: 717-726.
63. De Blois J, Simard S, Atar D, Agewall S, Norwegian Heart Failure Registry. COPD predicts mortality in HF: the Norwegian Heart Failure Registry. J Card Fail 2010; 16: 225-229.
64. Hawkins NM, Huang Z, Pieper KS, Solomon SD, Kober L, Velazquez EJ, Swedberg K, PfefferMA, McMurray JJ, MaggioniAP. Chronic obstructive pulmonary disease is an independent predictor of death but not atherosclerotic events in patients with myocardial infarction: analysis of the valsartan in acute myocardial infarction trial (VALIANT). Eur J Heart Fail 2009; 11: 292-298.
65. Staszewsky L, Wong M, Masson S, Barlera S, Carretta E, Maggioni AP, Anand IS, Cohn JN, Tognoni G, Latini R. Clinical, neurohormonal, and inflammatory markers and overall prognostic role of chronic obstructive pulmonary disease in patients with heart failure: data from the val-heft heart failure trial. J Card Fail 2007; 13: 797-804.
66. Kwon BJ, Kim DB, JangSW, Yoo KD, Moon KW, Shim BJ, Ahn SH, Cho EJ, Rho TH, Kim JH. Prognosis of heart failure patients with reduced and preserved ejection fraction and coexistent chronic obstructive pulmonary disease. Eur J Heart Fail 2010; 12: 1339-1344.
67. Boudestein LC, Rutten FH, Cramer MJ, LammersJW, HoesAW. The impact of concurrent heart failure on prognosis in patients with chronic obstructive pulmonary disease. Eur J Heart Fail 2009; 11: 1182-1188.
68. Janssen DJ, Spruit MA, Uszko-Lencer NH, Schols JM, Wouters EF. Symptoms, comorbidities, and health care in advanced chronic obstructive pulmonary disease or chronic heart failure. J Palliat Med 2011; 14: 735-743.
69. Walke LM, Byers AL, Tinetti ME, Dubin JA, McCorkle R, Fried TR. Range and severity of symptoms over time among older adults with chronic obstructive pulmonary disease and heart failure. Arch Intern Med 2007; 167: 2503-2508.
70. Milne EN. Correlation of physiologic findings with chest roentgenology. Radiol Clin North Am 1973; 11: 17-47.
71. Hublitz UF, Shapiro JH. Atypical pulmonary patterns of congestive failure in chronic lung disease. The influence of pre-existing disease on the appearance and distribution of pulmonary edema. Radiology 1969; 93: 995-1006.
72. Gehlbach BK, Geppert E. The pulmonary manifestations of left heart failure. Chest 2004; 125: 669-682.
73. Naum CC, Sciurba FC, Rogers RM. Pulmonary function abnormalities in chronic severe cardiomyopathy preceding cardiac transplantation. Am Rev Respir Dis 1992; 145: 1334-1338.
74. Wasserman K, Zhang YY, Gitt A, Belardinelli R, Koike A, Lubarsky L, Agostoni PG. Lung function and exercise gas exchange in chronic heart failure. Circulation 1997; 96: 2221-2227.
75. Hosenpud JD, Stibolt TA, Atwal K, Shelley D. Abnormal pulmonary function specifically related to congestive heart failure: comparison of patients before and after cardiac transplantation. Am J Med 1990; 88: 493-496.
76. DaganouM, Dimopoulou I, Alivizatos PA, Tzelepis GE. Pulmonary function and respiratory muscle strength in chronic heart failure: comparison between ischaemic and idiopathic dilated cardiomyopathy. Heart 1999; 81: 618-620.
77. Meyer FJ, Borst MM, Zugck C, Kirschke A, Schellberg D, KublerW, Haass M. Respiratory muscle dysfunction in congestive heart failure: clinical correlation and prognostic significance. Circulation 2001; 103: 2153-2158.
78. Guazzi M. Alveolar-capillary membrane dysfunction in heart failure: evidence of a pathophysiologic role. Chest 2003; 124: 1090-1102.
79. Guazzi M, Borlaug BA. Pulmonary hypertension due to left heart disease. Circulation 2012; 126: 975-990.
80. Guazzi M. Alveolar gas diffusion abnormalities in heart failure. J Card Fail 2008; 14: 695-702.
81. Guazzi M, Myers J, Vicenzi M, Bensimhon D, Chase P, Pinkstaff S, Arena R. Cardiopulmonary exercise testing characteristics in heart failure patients with and without concomitant chronic obstructive pulmonary disease. Am Heart J 2010; 160: 900-905.
82. Anonymous. Cardiac asthma. Lancet 1990; 335: 693-694.
83. Pison C, Malo JL, Rouleau JL, Chalaoui J, Ghezzo H, Malo J. Bronchial hyperresponsiveness to inhaled methacholine in subjects with chronic left heart failure at a time of exacerbation and after increasing diuretic therapy. Chest 1989; 96: 230-235.
84. LightRW, George RB. Serial pulmonary function in patients with acute heart failure. Arch Intern Med 1983; 143: 429-433.
85. PetermannW, Barth J, Entzian P. Heart failure and airway obstruction. Int J Cardiol 1987; 17: 207-209.
86. Rolla G, Bucca C, Brussino L, GalloW, Malara D. Bronchodilating effect of ipratropium bromide in heart failure. Eur Respir J 1993; 6: 1492-1495.
87. Faggiano P, Lombardi C, Sorgato A, Ghizzoni G, Spedini C, Rusconi C. Pulmonary function tests in patients with congestive heart failure: effects of medical therapy. Cardiology 1993; 83: 30-35.
88. Nagaya N, Nishikimi T, Uematsu M, Satoh T, Kyotani S, Sakamaki F, Kakishita M, Fukushima K, Okano Y, Nakanishi N, Miyatake K, Kangawa K. Plasma brain natriuretic peptide as a prognostic indicator in patients with primary pulmonary hypertension. Circulation 2000; 102: 865-870.
89. Bozkanat E, Tozkoparan E, Baysan O, Deniz O, Ciftci F, Yokusoglu M. The significance of elevated brain natriuretic peptide levels in chronic obstructive pulmonary disease. J Int Med Res 2005; 33: 537-544.
90. Rutten FH, Cramer MJ, Zuithoff NP, Lammers JW, Verweij W, Grobbee DE, Hoes AW. Comparison of B-type natriuretic peptide assays for identifying heart failure in stable elderly patients with a clinical diagnosis of chronic obstructive pulmonary disease. Eur J Heart Fail 2007; 9: 651-659.
91. Rutten FH, Moons KG, Cramer MJ, Grobbee DE, Zuithoff NP, Lammers JW, HoesAW. Recognising heart failure in elderly patients with stable chronic obstructive pulmonary disease in primary care: cross sectional diagnostic study. BMJ 2005; 331: 1379.
92. Boussuges A, Pinet C, Molenat F, Burnet H, Ambrosi P, Badier M, Sainty JM, Orehek J. Left atrial and ventricular filling in chronic obstructive pulmonary disease. An echocardiographic and Doppler study. Am J Respir Crit Care Med 2000; 162: 670-675.
93. Vizza CD, Lynch JP, Ochoa LL, Richardson G, Trulock EP. Right and left ventricular dysfunction in patients with severe pulmonary disease. Chest 1998; 113: 576-583.
94. McMurray JV, McDonagh TA, Davie AP, Cleland JG, Francis CM, Morrison C. Should we screen for asymptomatic left ventricular dysfunction to prevent heart failure? Eur Heart J 1998; 19: 842-846.
95. Wilson JMG, Jungner G. Principles and Practice of Screening for Disease. Public health papers no 34. Geneva: World Health Organization; 1968.
96. Grimes DA, Schulz KF. Uses and abuses of screening tests. Lancet 2002; 359: 881-884.
97. Calverley PM, Anderson JA, Celli B, Ferguson GT, Jenkins C, Jones PW, Yates JC, Vestbo J. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med 2007; 356: 775-789.
98. Karner C, Cates CJ. The effect of adding inhaled corticosteroids to tiotropium and long-acting beta(2)-agonists for chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2011; 9: CD009039.
99. TashkinDP, Celli B, Senn S, Burkhart D, Kesten S, Menjoge S, Decramer M.A4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med 2008; 359: 1543-1554.
100. Vogelmeier C, Hederer B, Glaab T, Schmidt H, Rutten-van Molken MP, Beeh KM, Rabe KF, Fabbri LM. Tiotropium versus salmeterol for the prevention of exacerbations of copd. N Engl J Med 2011; 364: 1093-1103.
101. Hawkins NM, Macdonald MR, Petrie MC, Chalmers GW, Carter R, Dunn FG, McMurray JJ. Bisoprolol in patients with heart failure and moderate to severe chronic obstructive pulmonary disease: a randomized controlled trial. Eur J Heart Fail 2009; 11: 684-690.
102. Lainscak M, Podbregar M, Kovacic D, Rozman J, von HS. Differences between bisoprolol and carvedilol in patients with chronic heart failure and chronic obstructive pulmonary disease: a randomized trial. Respir Med 2011; 105 (Suppl. 1): S44-S49.
103. Jabbour A, Macdonald PS, Keogh AM, Kotlyar E, Mellemkjaer S, Coleman CF, Elsik M, Krum H, Hayward CS. Differences between beta-blockers in patients with chronic heart failure and chronic obstructive pulmonary disease: a randomized crossover trial. J Am Coll Cardiol 2010; 55: 1780-1787.
104. Salpeter S, Ormiston T, Salpeter E. Cardioselective beta-blockers for chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2005: CD003566.
105. Dungen HD, Apostolovic S, Inkrot S, Tahirovic E, Topper A, Mehrhof F, Prettin C, Putnikovic B, Neskovic AN, Krotin M, Sakac D, Lainscak M, Edelmann F, Wachter R, Rau T, Eschenhagen T, DoehnerW, Anker SD, Waagstein F, Herrmann-Lingen C, Gelbrich G, Dietz R., investigators C-E, Project Multicentre Trials in the Competence Network Heart F. Titration to target dose of bisoprolol vs. Carvedilol in elderly patients with heart failure: The CIBIS-ELD trial. Eur J Heart Fail 2011; 13: 670-680.
106. Sin DD, McAlister FA. The effects of beta-blockers on morbidity and mortality in a population-based cohort of 11, 942 elderly patients with heart failure. Am J Med 2002; 113: 650-656.
107. Chen J, Radford MJ, Wang Y, Marciniak TA, Krumholz HM. Effectiveness of betablocker therapy after acute myocardial infarction in elderly patients with chronic obstructive pulmonary disease or asthma. J Am Coll Cardiol 2001; 37: 1950-1956.
108. Gottlieb SS, McCarter RJ, Vogel RA. Effect of beta-blockade on mortality among high-risk and low-risk patients after myocardial infarction. N Engl J Med 1998; 339: 489-497.
109. van Gestel YR, Hoeks SE, Sin DD, Welten GM, Schouten O, Witteveen HJ, Simsek C, Stam H, Mertens FW, Bax JJ, van Domburg RT, Poldermans D. Impact of cardioselective beta-blockers on mortality in patients with chronic obstructive pulmonary disease and atherosclerosis. Am J Respir Crit Care Med 2008; 178: 695-700.
110. Au DH, Bryson CL, Fan VS, Udris EM, Curtis JR, McDonell MB, Fihn SD. Betablockers as single-agent therapy for hypertension and the risk of mortality among patients with chronic obstructive pulmonary disease. Am J Med 2004; 117: 925-931.
111. Rutten FH, Zuithoff NP, Hak E, Grobbee DE, HoesAW. Beta-blockers may reduce mortality and risk of exacerbations in patients with chronic obstructive pulmonary disease. Arch Intern Med 2010; 170: 880-887.
112. Short PM, Lipworth SI, Elder DH, Schembri S, Lipworth BJ. Effect of beta blockers in treatment of chronic obstructive pulmonary disease: a retrospective cohort study. BMJ 2011; 342: d2549.
113. Etminan M, Jafari S, Carleton B, Fitzgerald JM. Beta-blocker use and COPD mortality: a systematic review and meta-analysis. BMC Pulm Med 2012; 12: 48.
114. Bristow MR, Ginsburg R, Umans V, Fowler M, Minobe W, Rasmussen R, Zera P, Menlove R, Shah P, Jamieson S. Beta 1- and beta 2-adrenergic-receptor subpopulations in nonfailing and failing human ventricular myocardium: coupling of both receptor subtypes to muscle contraction and selective beta 1-receptor down-regulation in heart failure. Circ Res 1986; 59: 297-309.
115. Packer M. Pathophysiologicalmechanisms underlying the effects of beta-adrenergic agonists and antagonists on functional capacity and survival in chronic heart failure. Circulation 1990; 82: I77-I88.
116. Cazzola M, Matera MG, Donner CF. Inhaled beta2-adrenoceptor agonists: cardiovascular safety in patients with obstructive lung disease. Drugs 2005; 65: 1595-1610.
117. Salpeter SR, Ormiston TM, Salpeter EE. Cardiovascular effects of beta-agonists in patients with asthma and COPD: a meta-analysis. Chest 2004; 125: 2309-2321.
118. Bremner P, Woodman K, Burgess C, Crane J, Purdie G, Pearce N, Beasley R.Acomparison of the cardiovascular and metabolic effects of formoterol, salbutamol and fenoterol. Eur Respir J 1993; 6: 204-210.
119. Jartti T, Kaila T, Tahvanainen K, Kuusela T, Vanto T, Valimaki I. The acute effects of inhaled salbutamol on the beat-to-beat variability of heart rate and blood pressure assessed by spectral analysis. Br J Clin Pharmacol 1997; 43: 421-428.
120. Au DH, Curtis JR, Every NR, McDonell MB, Fihn SD. Association between inhaled beta-agonists and the risk of unstable angina and myocardial infarction. Chest 2002; 121: 846-851.
121. Bermingham M, O'Callaghan E, Dawkins I, Miwa S, Samsudin S, McDonald K, Ledwidge M. Are beta2-agonists responsible for increased mortality in heart failure? Eur J Heart Fail 2011; 13: 885-891.
122. Mentz RJ, Fiuzat M, Kraft M, Lindenfeld J, O'Connor CM. Bronchodilators in heart failure patients with COPD: is it time for a clinical trial? J Card Fail 2012; 18: 413-422.
123. Vestbo J, Anderson J, Brook RD, Calverley PM, Celli BR, Crim C, Haumann B, Martinez FJ, Yates J, Newby DE. The study to understand mortality and morbidity in COPD (summit) study protocol. Eur Respir J 2013; 41: 1017-1022.
124. Agostoni P, Contini M, Cattadori G, Apostolo A, Sciomer S, Bussotti M, Palermo P, Fiorentini C. Lung function with carvedilol and bisoprolol in chronic heart failure: is beta selectivity relevant? Eur J Heart Fail 2007; 9: 827-833.
125. Hawkins NM, Wang D, Petrie MC, Pfeffer MA, Swedberg K, Granger CB, Yusuf S, Solomon SD, Ostergren J, Michelson EL, Pocock SJ, MaggioniAP, McMurray JJ. Baseline characteristics and outcomes of patients with heart failure receiving bronchodilators in the charm programme. Eur J Heart Fail 2010; 12: 557-565.
126. Mueller C, Scholer A, Laule-Kilian K, Martina B, Schindler C, Buser P, Pfisterer M, Perruchoud AP. Use of B-type natriuretic peptide in the evaluation and management of acute dyspnea. N Engl J Med 2004; 350: 647-654.
127. Wang CS, FitzGerald JM, Schulzer M, Mak E, AyasNT. Does this dyspneic patient in the emergency department have congestive heart failure? JAMA 2005; 294: 1944-1956.
128. Maisel AS, Krishnaswamy P, Nowak RM, McCord J, Hollander JE, Duc P, Omland T, Storrow AB, Abraham WT, Wu AH, Clopton P, Steg PG, Westheim A, KnudsenCW, Perez A, Kazanegra R, Herrmann HC, McCullough PA. Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure.N Engl J Med 2002; 347: 161-167.
129. Morrison LK, Harrison A, Krishnaswamy P, Kazanegra R, Clopton P, Maisel A. Utility of a rapid B-natriuretic peptide assay in differentiating congestive heart failure from lung disease in patients presenting with dyspnea. JAmColl Cardiol 2002; 39: 202-209.
130. Simon-Tuval T, Scharf SM, Maimon N, Bernhard-Scharf BJ, Reuveni H, Tarasiuk A. Determinants of elevated healthcare utilization in patients with COPD. Respir Res 2011; 12: 7.
131. Sharafkhaneh A, Petersen NJ, Yu HJ, Dalal AA, Johnson ML, Hanania NA. Burden of COPD in a government health care system: a retrospective observational study using data from the us veterans affairs population. Int J Chron Obstruct Pulmon Dis 2010; 5: 125-132.
132. Mapel DW, Hurley JS, Frost FJ, Petersen HV, Picchi MA, Coultas DB. Health care utilization in chronic obstructive pulmonary disease. A case-control study in a health maintenance organization. Arch Intern Med 2000; 160: 2653-2658.
133. Sullivan SD, Ramsey SD, Lee TA. The economic burden of COPD. Chest 2000; 117: 5S-9S.
134. Berry C, Murdoch DR, McMurray JJ. Economics of chronic heart failure. Eur J Heart Fail 2001; 3: 283-291.
135. Priest JL, Cantrell CR, Fincham J, CookCL, Burch SP. Quality of care associated with common chronic diseases in a 9-state medicaid population utilizing claims data: an evaluation of medication and health care use and costs. Popul Health Manag 2011; 14: 43-54.
136. Stewart S, Jenkins A, Buchan S, McGuire A, Capewell S, McMurray JJ. The current cost of heart failure to the national health service in the UK. Eur J Heart Fail 2002; 4: 361-371.
137. Foster TS, Miller JD, Marton JP, Caloyeras JP, RussellMW, Menzin J. Assessment of the economic burden of COPDin the U.S.: a reviewand synthesis of the literature. COPD 2006; 3: 211-218.
138. Liao L, Anstrom KJ, Gottdiener JS, Pappas PA, Whellan DJ, Kitzman DW, Aurigemma GP, Mark DB, Schulman KA, Jollis JG. Long-term costs and resource use in elderly participants with congestive heart failure in the cardiovascular health study. Am Heart J 2007; 153: 245-252.
139. Davey PG, Clarkson PB, McMahon A, MacDonald TM. Costs associated with symptomatic systolic heart failure. Pharmacoeconomics 1999; 16: 399-407.
140. Hilleman DE, Dewan N, Malesker M, Friedman M. Pharmacoeconomic evaluation of COPD. Chest 2000; 118: 1278-1285.
141. Gerdtham UG, Andersson LF, Ericsson A, Borg S, Jansson SA, Ronmark E, Lundback B. Factors affecting chronic obstructive pulmonary disease (COPD)-related costs: a multivariate analysis of a swedish COPD cohort. Eur J Health Econ 2009; 10: 217-226.
142. Lin PJ, Shaya FT, Scharf SM. Economic implications of comorbid conditions among medicaid beneficiaries with COPD. Respir Med 2010; 104: 697-704.
143. Hutchinson A, Brand C, Irving L, Roberts C, Thompson P, Campbell D. Acute care costs of patients admitted for management of chronic obstructive pulmonary disease exacerbations: contribution of disease severity, infection and chronic heart failure. Intern Med J 2010; 40: 364-371.
144. Braunstein JB, Anderson GF, Gerstenblith G, Weller W, Niefeld M, Herbert R, WuAW. Noncardiac comorbidity increases preventable hospitalizations and mortalityamong medicarebeneficiaries with chronic heart failure. JAmColl Cardiol 2003; 42: 1226-1233.
145. Krumholz HM, Parent EM, Tu N, Vaccarino V, Wang Y, Radford MJ, Hennen J. Readmission after hospitalization for congestive heart failure among medicare beneficiaries. Arch Intern Med 1997; 157: 99-104. Office CB High-Cost Medicare Beneficiaries. Congress of the United States Congressional Budget Office.
146. Office CB. High-Cost Medicare Beneficiaries. Congress of the United States Congressional Budget Office. 147. Swedberg K, Komajda M, Bohm M, Borer JS, Ford I, Dubost-Brama A, Lerebours G, Tavazzi L. Ivabradine and outcomes in chronic heart failure (shift): a randomised placebo-controlled study. Lancet 2010; 376: 875-885.
147. Metra M, Cotter G, Gheorghiade M, Dei Cas L, Voors AA. The role of the kidney in heart failure. Eur Heart J 2012; 33: 2135-2142.
148. Macchia A, Monte S, RomeroM, D'Ettorre A, Tognoni G. The prognostic influence of chronic obstructive pulmonary disease in patients hospitalised for chronic heart failure. Eur J Heart Fail 2007; 9: 942-948.
149. Lainscak M, Hodoscek LM, Dungen HD, Rauchhaus M, Doehner W, Anker SD, von HS. The burden of chronic obstructive pulmonary disease in patients hospitalized with heart failure. Wien Klin Wochenschr 2009; 121: 309-313.
150. Mentz RJ, Fiuzat M, Wojdyla DM, Chiswell K, Gheorghiade M, Fonarow GC, O'Connor CM. Clinical characteristics and outcomes of hospitalized heart failure patients with systolic dysfunction and chronic obstructive pulmonary disease: findings from optimize-HF. Eur J Heart Fail 2012; 14: 395-403.
151. Dransfield MT, Rowe SM, Johnson JE, Bailey WC, Gerald LB. Use of beta blockers and the risk of death in hospitalised patients with acute exacerbations of copd. Thorax 2008; 63: 301-305.
152. Martin RM, Dunn NR, Freemantle SN, Mann RD. Risk of non-fatal cardiac failure and ischaemic heart disease with long acting beta 2 agonists. Thorax 1998; 53: 558-562.
153. Coughlin SS, Metayer C, McCarthy EP, Mather FJ, Waldhorn RE, Gersh BJ, DuPraw S, Baughman KL. Respiratory illness, beta-agonists, and risk of idiopathic dilated cardiomyopathy. The Washington, DC, dilated cardiomyopathy study. Am J Epidemiol 1995; 142: 395-403.
154. Sengstock DM, Obeidat O, Pasnoori V, Mehra P, Sandberg KR, McCullough PA. Asthma, beta-agonists, and development of congestive heart failure: results of the ABCHF study. J Card Fail 2002; 8: 232-238.
155. Macie C, Wooldrage K, Manfreda J, Anthonisen N. Cardiovascular morbidity and the use of inhaled bronchodilators. Int J Chron Obstruct Pulmon Dis 2008; 3: 163-169.
156. Au DH, Udris EM, Curtis JR, McDonell MB, Fihn SD. Association between chronic heart failure and inhaled beta-2-adrenoceptor agonists. Am Heart J 2004; 148: 915-920.
157. Au DH, Udris EM, Fan VS, Curtis JR, McDonell MB, Fihn SD. Risk of mortality and heart failure exacerbations associated with inhaled beta-adrenoceptor agonists among patients with known left ventricular systolic dysfunction. Chest 2003; 123: 1964-1969.
158. Singer AJ, Emerman C, Char DM, Heywood JT, Kirk JD, Hollander JE, Summers R, Lee CC, Wynne J, Kellerman L, Peacock WF. Bronchodilator therapy in acute decompensated heart failure patients without a history of chronic obstructive pulmonary disease. Ann Emerg Med 2008; 51: 25-34.